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To the Editor I am writing with regards to the ar‑
ticle by Sułowicz et al.1 I would like to thank 
the authors for raising the issue of infectious 
dermatological complications linked to immuno‑
suppressive therapy after solid organ transplanta‑
tion. The authors investigated the epidemiology 
of skin viral infections among kidney transplant 
recipients in great detail. Skin problems, of which 
skin viral infections are the most common, seri‑
ously affect the quality of life of transplant recip‑
ients. Skin infection is not only a serious medi‑
cal problem but also a cosmetic nuisance. In our 
studies, patients highlighted the cosmetic aspect 
as one of the most important problems affecting 
their quality of life.
The study1 involved a large group of 486 pa‑
tients of an outpatient clinic at the Department 
of Nephrology, Jagiellonian University Hospi‑
tal, Kraków, Poland. They underwent a detailed 
subjective and physical examination for the pres‑
ence of any skin lesions and potential risk fac‑
tors for their development. A viral cutaneous le‑
sion was observed in 189 individuals (38.9%), of 
which 98.9% were viral warts. Two patients had 
herpes zoster infection. Cutaneous viral lesions 
were observed mainly in men, older patients, and 
with longer follow‑up period after transplanta‑
tion. The most common location of the lesion 
were the hands and feet. The model of a careful 
follow‑up after diagnosing a skin viral infection, 
as proposed by the authors,1 can also be success‑
fully applied in skin cancer (a leading type of neo‑
plasms in recipients).
Another aspect that drew the authors’ atten‑
tion was the effect of the immunosuppressive reg‑
imen on the incidence of viral cutaneous lesions. 
It was proved that individuals treated with cyclo‑
sporine A and azathioprine are especially prone 
to skin viral infection. On the other hand, tacro‑
limus and mycophenolate mofetil were described 
to cause those lesions significantly less frequent‑
ly. The authors used complex and exact statisti‑
cal methods to describe the data. It will be even 
more interesting to look at the blood immuno‑
suppressant level rather than at the daily doses. 
Another interesting issue is induction therapy 
with mono‑ and polyclonal antibodies. In many 
studies, it seems to be an important risk factor 
for later viral complications including infection 
with potentially oncogenic viruses. For this rea‑
son, Muromonab‑CD3 (Orthoclone OKT3) is no 
longer used. In my opinion, using T‑cell depletion 
therapy requires the monitoring of the absolute 
CD3 cell count by flow cytometry. Maintaining 
the CD3 level between 50 and 80 cells/mm3 could 
potentially prevent later viral and neoplastic com‑
plications. This hypothesis requires more accurate 
studies in the future. Another interesting finding 
is that the use of azathioprine was a risk factor of 
skin viral infection, and the authors’ view on this 
issue would be of particular interest.
Skin lesions after solid organ transplantation 
are one of the most common side effects of an im‑
munosuppressive therapy. It is of great impor‑
tance to examine any new lesion because the in‑
cidence of skin malignancies is elevated in this 
population of patients. The authors did not men‑
tion whether any of the lesions was neoplastic or 
whether it progressed to a dysplastic lesion during 
the follow‑up period. This issue seems to be cru‑
cial because skin neoplasms in the population of 
solid organ transplant recipients are particularly 
malignant. Another aspect that could have been 
reported in greater detail is the number of skin vi‑
ral lesions characterized in particular individuals 
and whether there was any significance between 
the time after transplantation or immunosup‑
pressive regimen and the number of viral warts. 
Additionally, viral warts on the hands could have 
been described more precisely. A number of au‑
thors differentiate between the warts on the back 
of the hands (which are more common) and palms 
(which are more painful and troublesome).2
In 2003, Schmook et al.3 reported that the ad‑
equate treatment for multiple warts caused by 
human papillomavirus in organ transplant re‑
cipients needs to be effective because warts per‑
sist over years and the rate of spontaneous remis‑
sion is extremely low. Moreover, some of these 
viral warts may present with atypical histological 
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features and may progress to squamous cell car‑ 
cinoma.4 Shmook et al.3 described the avail‑ 
able treatment methods and proposed a prom‑ 
ising novel therapy with imiquimod. Sułowicz 
et al.1 did not present data on the treatment of vi‑ 
ral warts and did not address the issue of wheth‑ 
er the treatment was necessary in any individu‑ 
al, what was the treatment administered, if any, 
and what was its effectiveness.
The final issue that has recently drawn the at‑ 
tention of researchers in many disease states is 
the quality of life. The authors1 discussed this in 
the introduction, but did not report any data. In 
2012, Zachariae et al.2 published a study on Dan‑ 
ish kidney transplant patients, in which they ex‑ 
amined the quality of life of individuals suffer‑ 
ing from viral warts. They suggested the use of 
the Dermatology Quality of Life Index.5 Sułowicz 
et al.1 did not report whether patients with a vi‑ 
ral cutaneous infection complained of a decreased 
quality of life and whether they thus demonstrat‑ 
ed a stronger motivation to receive an adequate 
treatment.
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